MedTrace Logo

Febuxostat, Blood Pressure and the Intrarenal Renin-Angiotensin System (RAS)

NCT01328769 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2015-09-17

Study results available
· View outcomes & findings →

Summary

In this study the investigators will recruit hypertensive subjects with higher than average uric acid levels to test the effect of lowering uric acid with febuxostat on several measures as listed below. This will be a randomized, double-blind, placebo-controlled, parallel group study.

Conditions

Interventions

DRUG

Febuxostat

DRUG

Placebo

Sponsors & Collaborators

  • Paul N. Hopkins

    lead OTHER

Principal Investigators

  • Paul N Hopkins · Cardiovascular Genetics

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2013-09-30
Completion
2014-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01328769 on ClinicalTrials.gov